Curr Opin Rheumatol. 2018 Jan;30(1):50-56. doi: 10.1097/BOR.0000000000000458.
To give an overview of recently published articles about the management of vasculo-Behcet's with particular emphasis on anticoagulation.
Biologic agents are emerging as a potential therapeutic option in refractory vasculo-Behcet with a good safety profile. Evidence further shows that following nonpulmonary aneurysm repair, there is a reduced risk of recurrent aneurysmal formation at the operative site in patients treated with immunosuppressants in addition to their surgery, than those undergoing surgical intervention alone.
Behcet disease patients are at risk of developing multiple vascular complications including thrombosis and aneurysms. Treatment should focus on reducing inflammation; and the role of anticoagulation is still debatable.
介绍近期发表的关于血管白塞病管理的文章，特别强调抗凝治疗。
生物制剂作为一种潜在的治疗选择，在难治性血管白塞病中具有良好的安全性。进一步的证据表明，在非肺动脉瘤修复后，与单独手术治疗相比，接受免疫抑制剂治疗的患者在手术部位的复发性动脉瘤形成风险降低。
白塞病患者发生多种血管并发症（包括血栓形成和动脉瘤）的风险增加。治疗应侧重于减少炎症；抗凝治疗的作用仍存在争议。
